LSTA

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). LSTA1 also has the potential to modify the tumor microenvironment. It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. In addition, it has clinical development programs based on its autologous CD34+ cell therapy technology platform.